Three people with brain injury symptoms improved during low-dose iboga plus therapy

The question

Could a six-week program of low-dose iboga root bark, combined with weekly psychotherapy and supplements, help people with lingering symptoms after a traumatic or oxygen-deprivation brain injury?

What they did

Three people took part: a 43-year-old man with a brain injury from a motorcycle crash, a 40-year-old woman with chronic brain injury from oxygen deprivation after being buried in an avalanche, and a 19-year-old woman with a brain injury from a car crash. Over six weeks they self-adjusted their dose of Tabernanthe iboga root bark, taking 0.1 to 1.0 g per day on a four-days-on, three-days-off schedule. Lab analysis found the bark contained about 3.845% ibogaine by mass, giving an estimated 3.8 to 38.5 mg of ibogaine per day. They also received weekly Accelerated Experiential Dynamic Psychotherapy and nutritional supplements, and were screened beforehand for heart problems and drug interactions.

What they found

All three reported gradual neurological improvement over the six weeks, and two reported complete remission of symptoms at a later follow-up. Starting symptoms included daily headaches, episodic migraines, balance problems, irritability, mood swings, fatigue, brain fog, disrupted sleep and loss of interest in usual activities. By the end of the protocol and at follow-up, all three said they were able to stop all prescription medications for symptom relief and reported no severe migraines, along with resolution of brain fog, fatigue and irritability, more stable mood, and a return to regular activities. The authors state plainly that the findings do not establish cause and effect or show that iboga specifically was responsible.

The fine print

With only three people, no control group, no blinding and no placebo, improvement could reflect natural recovery over time, expectation, or the psychotherapy and supplements rather than the iboga. Outcomes were self-reported symptoms rather than standardized tests, participants chose their own doses, and the abstract does not say how long follow-up lasted. Iboga carries known heart rhythm risks, which is why participants were screened; this summary is based on the abstract alone.

What it means

This is an early, hypothesis-generating report: three people improved during a combined iboga-and-therapy program, but the design cannot tell us whether the iboga made the difference. Controlled trials would be needed to answer that.

Evidence grade: Very low. This is an uncontrolled case series of only three people, with self-reported symptoms and no comparison group, so it cannot show that the iboga caused the changes.

This summary is based on the study’s published abstract.